HRH2 and melanoma: That is, it was reported that H1R antagonist (mepyramine) and H2R antagonists (cimetidine, ranitidine, impromidine) increased TYR activity in cultured human melanoma cells, whereas H2R agonists (dimaprit, nordimaprit) decreased the activity (Figure 6) [155].